tbuckley/cabot-search huggingface dataset:
Improvement of some schizophrenic deficit symptoms with low doses of amisulpride
Authors: M L Paillère-Martinot, Y Lecrubier, J L Martinot, F Aubin
Journal: American Journal of Psychiatry (1995)

The authors assessed the effects on primary negative symptoms of low doses of amisulpride, a substituted benzamide neuroleptic with high affinity for D2 and D3 dopamine receptors.Young, drug-free schizophrenic patients with pure negative symptoms participated in a 6-week double-blind trial of placebo (N = 10) or low-dose amisulpride (N = 10). They were assessed with the Scale for the Assessment of Negative Symptoms.Amisulpride significantly improved negative symptoms. Improvement in avolition, attentional impairment, and retardation was significantly greater with amisulpride than with placebo.These findings suggest that some primary negative symptoms may be directly affected by low doses of benzamide neuroleptics.
Surface-modified liposomes for syndecan 2–targeted delivery of edelfosine
Authors: Gayong Shim, Yong Hee Yu, Soondong Lee, Jinyoung Kim, Yu-Kyoung Oh
Journal: Asian Journal of Pharmaceutical Sciences (2016)

Here, we report that the modification of liposome surfaces with AG73 peptides enhances delivery of the lipophilic anticancer drug, edelfosine, to tumor cells overexpressing the cell-surface receptor, syndecan 2. To test the effect of liposomal surface density of AG73 peptides on cellular uptake, we synthesized AG73 peptide-conjugated polyethylene glycol (MW 2000) lipid and incorporated it into fluorescence dye-labeled anionic liposomes with different ligand densities (1, 2, or 5 mol% of total lipids). Cellular uptake of AG73-peptide–modified liposomes gradually increased in proportion to the surface ligand density. The percentages of cells positive for AG73-modified, fluorescent-dye–labeled liposomes were 19.8 ± 2.0%, 23.1 ± 5.0%, and 99.2 ± 1.0%, for ligand mole percentages of 1, 2, and 5, respectively. The cell-targeting ability of AG73-modified liposomes was not significantly altered by the serum content of culture media. In keeping with the observed enhanced cellular uptake, AG73-peptide–modified liposomes entrapping edelfosine exhibited greater cancer cell-killing effects compared with unmodified liposomes. Following intravenous administration into tumor-bearing mice, AG73-peptide–modified liposomes showed 2.1-fold greater accumulation in tumors than unmodified liposomes. These results support the feasibility of using syndecan 2–directed liposomes for delivery of edelfosine.
Familial tardive dyskinesia
Authors: R Yassa, J Ananth
Journal: American Journal of Psychiatry (1981)

The authors surveyed 500 inpatients receiving long-term neuroleptics; 8 had first-degree family members who were also being treated with long-term neuroleptics and suffering from a psychiatric disorder. The 8 patient-relative pairs showed concordance for the presence or absence of tardive dyskinesia.
Medicaid Audit: Crisis in Confidentiality and the Patient-Psychiatrist Relationship
Authors: Harvey J. Shwed, Seymour F. Kuvin, Ravi K. Baliga
Journal: American Journal of Psychiatry (1979)

The authors describe their experience with a routine Medicaid audit and discuss the damage such a procedure can do to the trust between psychiatrists and patients, confidentiality, doctors' reputations, transference reactions, and patients' own emotional states. The authors point out that these crucial issues have broad implications because of the possibility of passage of national health insurance legislation.
Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis
Authors: Maya H Buch, Josef S Smolen, Neil Betteridge, Ferdinand C Breedveld, Gerd Burmester, Thomas Dörner, Gianfranco Ferraccioli, Jacques-Eric Gottenberg, John Isaacs, Tore K Kvien, Xavier Mariette, Emilio Martin-Mola, Karel Pavelka, Paul P Tak, Desiree van der Heijde, Ronald F van Vollenhoven, Paul Emery
Journal: Annals of the Rheumatic Diseases (2011)

Background Since initial approval for the treatment of rheumatoid arthritis (RA), rituximab has been evaluated in clinical trials involving various populations with RA. Information has also been gathered from registries. This report therefore updates the 2007 consensus document on the use of rituximab in the treatment of RA. Methods Preparation of this new document involved many international experts experienced in the treatment of RA. Following a meeting to agree upon the core agenda, a systematic literature review was undertaken to identify all relevant data. Data were then interrogated by a drafting committee, with subsequent review and discussion by a wider expert committee leading to the formulation of an updated consensus statement. These committees also included patients with RA. Results The new statement covers wide-ranging issues including the use of rituximab in earlier RA and impact on structural progression, and aspects particularly pertinent to rituximab such as co-medication, optimal dosage regimens, repeat treatment cycles and how to manage non-response. Biological therapy following rituximab usage is also addressed, and safety concerns including appropriate screening for hepatitis, immunoglobulin levels and infection risk. This consensus statement will support clinicians and inform patients when using B-cell depletion in the management of RA, providing up-to-date information and highlighting areas for further research. Conclusion New therapeutic strategies and treatment options for RA, a chronic destructive and disabling disease, have expanded over recent years. These have been summarised in general strategic suggestions and specific management recommendations, emphasising the importance of expedient disease-modifying antirheumatic drug implementation and tight disease control. This consensus statement is in line with these fundamental principles of management.
Soundings: Staying put
Authors: Trisha Greenhalgh
Journal: BMJ (2000)

She had had what is known in the trade as a “fair innings.” It was 15 years since my predecessor first raised the suggestion that she would be more comfortable in a residential home. She had resisted. Long before it became a standard package option for octogenarians, she had negotiated with a mortgage company to release her assets, and paid for home adaptations and a long string of live-in helpers. Today, she was dying—in a triumphant sort of way.

Five years ago, she had moved the bed downstairs into an alcove in the front room. From here, she could see through the French windows into her little garden. When I came to visit, she always talked me through the plants' latest ailments before starting on her own.

Towards the end, I began to share her concern that she would outlive the clematis, which had never really picked up since the winter frost. Her gardener was kept busy to the last, and when I told her she had pneumonia—“That might be it, is that what you're saying, doctor?”—she made sure she put an extra fiver in his envelope.

Her parlour was modestly but comfortably furnished, with three separate coffee tables and a selection of not quite matching armchairs. Various friends and neighbours gathered in silence, reading her magazines and drinking her tea. They knew they didn't feature in her will—she'd announced long ago that she intended to leave it all to charity—but when you have lived in the same cul-de-sac for 40 years you turn up to pay your last respects. At one stage, I evicted them all into the hall on the pretext of wanting to listen to her chest, and asked if she would prefer to be alone. “No, thank you, doctor,” she gasped. “But can you make sure they wash the cups up after I've gone?”

The vicar came and went, twice, and I popped in and out between surgeries. Some distant nieces and nephews phoned up. At 5 pm she asked for tea in her beaker and sucked on some toast. At a quarter past she breathed her last.

The undertakers nodded a greeting to me and began to load her up on their portable stretcher. “Nice place,” they muttered, indicating the view from the window. “Did well to stay put, didn't she?”
Verteporfin in Photodynamic Therapy: Report no. 5
Authors: Francesco Bandello, Kevin Blinder, Neil M Bressler, Alison L Brown, Joan W Miller, Michael J Potter, Constantin Pournaras, Al Reaves, Philip J Rosenfeld, Jason S Slakter, Gisele Soubrane, H Andrew Strong, Michael Stur
Journal: Ophthalmology (2004)
A randomised phase II study evaluating the efficacy and safety of subcutaneously administered ustekinumab and guselkumab in patients with active rheumatoid arthritis despite treatment with methotrexate
Authors: Josef S Smolen, Sandeep K Agarwal, Elena Ilivanova, Xie Lillian Xu, Ye Miao, Yanli Zhuang, Ivo Nnane, Waldemar Radziszewski, Andrew Greenspan, Anna Beutler, Daniel Baker
Journal: Annals of the Rheumatic Diseases (2017)

Objective Interleukin (IL)-12 and IL-23 have been implicated in the pathogenesis of rheumatoid arthritis (RA). The safety and efficacy of ustekinumab, a human monoclonal anti-IL-12/23 p40 antibody, and guselkumab, a human monoclonal anti-IL-23 antibody, were evaluated in adults with active RA despite methotrexate (MTX) therapy. Methods Patients were randomly assigned (1:1:1:1:1) to receive placebo at weeks 0, 4 and every 8 weeks (n=55), ustekinumab 90 mg at weeks 0, 4 and every 8 weeks (n=55), ustekinumab 90 mg at weeks 0, 4 and every 12 weeks (n=55), guselkumab 50 mg at weeks 0, 4 and every 8 weeks (n=55), or guselkumab 200 mg at weeks 0, 4 and every 8 weeks (n=54) through week 28; all patients continued a stable dose of MTX (10–25 mg/week). The primary end point was the proportion of patients with at least a 20% improvement in the American College of Rheumatology criteria (ACR 20) at week 28. Safety was monitored through week 48. Results At week 28, there were no statistically significant differences in the proportions of patients achieving an ACR 20 response between the combined ustekinumab group (53.6%) or the combined guselkumab group (41.3%) compared with placebo (40.0%) (p=0.101 and p=0.877, respectively). Through week 48, the proportions of patients with at least one adverse event (AE) were comparable among the treatment groups. Infections were the most common type of AE. Conclusions Treatment with ustekinumab or guselkumab did not significantly reduce the signs and symptoms of RA. No new safety findings were observed with either treatment. Trial registration number NCT01645280 .
Gnb isoforms control a signaling pathway comprising Rac1, Plcβ2, and Plcβ3 leading to LFA-1 activation and neutrophil arrest in vivo
Authors: Helena Block, Anika Stadtmann, Daniel Riad, Jan Rossaint, Charlotte Sohlbach, Giulia Germena, Dianqing Wu, Scott I. Simon, Klaus Ley, Alexander Zarbock
Journal: Blood (2015)
Single Cell Genetic Analysis Helps Validating Cytopathological Identification of Ctcs in Patients with Ccrc
Authors: Patrizia Paterlini-Brechot, Basma Ben Njima, Paul Hofman, Veronique Hofman, Marius Ilie, Habiba Chaabouni, Raoudha Doghri, Khaled Ben Romdhane
Journal: Annals of Oncology (2014)
Workshop on Epstein-Barr Virus: Summary and Recommendations
Authors: D.V. Ablashi, H.G. Aaslestad, G. de-Thé
Journal: JNCI Journal of the National Cancer Institute (1976)

Journal Article Workshop on Epstein-Barr Virus: Summary and Recommendations Get access D.V. Ablashi, D.V. Ablashi Search for other works by this author on: Oxford Academic PubMed Google Scholar H.G. Aaslestad, H.G. Aaslestad Search for other works by this author on: Oxford Academic PubMed Google Scholar G. de-Thé G. de-Thé Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 56, Issue 2, February 1976, Page 451, https://doi.org/10.1093/jnci/56.2.451 Published: 01 February 1976
Determination of Peripheral Blood Pressure in Unanesthetized Mice During Microscopic Observation of Blood Vessels&lt;xref ref-type="fn" rid="fn1"&gt;2&lt;/xref&gt;
Authors: Glenn H. Algire
Journal: JNCI Journal of the National Cancer Institute (1954)

Journal Article Determination of Peripheral Blood Pressure in Unanesthetized Mice During Microscopic Observation of Blood Vessels Get access Glenn H. Algire Glenn H. Algire National Cancer Institute,3Bethesda, Md. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 14, Issue 4, February 1954, Pages 865–877, https://doi.org/10.1093/jnci/14.4.865 Published: 01 February 1954 Article history Received: 24 August 1953 Published: 01 February 1954
AB0463 Serum Levels of MIR-203 Predict a Positive Response to Tocilizumab Therapy in Rheumatoid Arthritis Patients
Authors: J. Feld, D. Zisman, M. Elias, E. Hoffman, A. Kinarty, M.A. Rahat
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Dysregulated expression levels of different microRNAs are reported in both serum and inflamed joints of RA patients. <h3>Objectives</h3> To determine whether administration of Tocalizumab (TCZ), a neutralizing anti-IL-6 receptor antibody, changes expression levels of selected miRNAs, which were previously described in the context of RA. <h3>Methods</h3> 40 RA patients diagnosed with moderate to severe disease activity according to both DAS28 and CDAI scores, and were started on TCZ therapy, were enrolled in the study. Serum samples that were obtained before treatment and 4 months after TCZ treatment initiation, were analyzed for the relative expression of miR-16, -21, -132, -146a, -150, -155, -203, -221, and -323 by qPCR. <h3>Results</h3> No significant changes in the expression levels of the tested miRNAs were found after TCZ treatment. However, when patients were stratified to responders and non-responders according to both the CDAI and DAS28 scores, the levels of miR-203 alone, out of the 9 miRNAs examined, were increased by 8.2% (p&lt;0.0335) only in the responding group after 4 months of TCZ treatment, relative to the no-responders. <h3>Conclusions</h3> The expression levels of miR-203 could serve as a potential biomarker that predicts a positive response to TCZ treatment in RA patients. <h3>References</h3> O9Connell, R. M., Rao, D. S., Baltimore, D. (2012) microRNA regulation of inflammatory responses. Annu Rev Immunol 30, 295-312. Fu, L., Jin, L., Yan, L., Shi, J., Wang, H., Zhou, B., Wu, X. (2014) Comprehensive review of genetic association studies and meta-analysis on miRNA polymorphisms and rheumatoid arthritis and systemic lupus erythematosus susceptibility. Hum Immunol Sep 2014. Bottini, N. and Firestein, G. S. (2013) Epigenetics in rheumatoid arthritis: a primer for rheumatologists. Curr Rheumatol Rep 15, 372. Duroux-Richard, I., Jorgensen, C., Apparailly, F. (2012) What do microRNAs mean for rheumatoid arthritis? Arthritis Rheum 64, 11-20. Murata, K., Yoshitomi, H., Tanida, S., Ishikawa, M., Nishitani, K., Ito, H., Nakamura, T. (2010) Plasma and synovial fluid microRNAs as potential biomarkers of rheumatoid arthritis and osteoarthritis. Arthritis research &amp; therapy 12, R86. Stanczyk, J., Ospelt, C., Karouzakis, E., Filer, A., Raza, K., Kolling, C., Gay, R., Buckley, C. D., Tak, P. P., Gay, S., Kyburz, D. (2011) Altered expression of microRNA-203 in rheumatoid arthritis synovial fibroblasts and its role in fibroblast activation. Arthritis Rheum 63, 373-81. <h3>Acknowledgements</h3> The first and second authors are equal contributors. <h3>Disclosure of Interest</h3> None declared
SAT0011 An IL-32 Promoter SNP Associated with Lower HDL and Anti-CCP Promoting Atherosclerosis in RA
Authors: B. Heinhuis, M. Damen, S. Holewijn, J. de Graaf, J. Fransen, C. Popa, L. Joosten
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> The association between rheumatoid arthritis (RA) and cardiovascular diseases (CVD) is well established [1]. Interleukin (IL)-32, a highly expressed proinflammatory cytokine in RA [2] might play a key role in both processes. We have recently reported that IL-32 expression is enhanced in human atherosclerotic plaques, while overexpression of IL-32 produced more proatherosclerotic mediators [3]. Interestingly, the expression of IL-32 might be regulated by single nucleotide polymorphisms (SNPs) located in the promoter region of the gene. <h3>Objectives</h3> Firstly to determine whether SNP rs4786370 located in the promoter region of IL-32 is associated with IL-32 expression; secondly to investigate possible association of the SNP with several traditional CV risk factors in a control cohort and a group of patients with RA. <h3>Methods</h3> HUVEC cells from different donors were used to determine the IL-32 promoter SNP and IL-32 expression. DNA samples from individuals from the Nijmegen Biomedical Study were used to determine the IL-32 promoter SNP by Taqman assay and to associate with different CV risk factors such as lipoprotein profile. Finally, similar associations have been performed using DNA samples and other data from several RA cohorts. <h3>Results</h3> HUVEC cells with the TT-genotype displayed more IL-32 expression than the CC-genotype. In the general population cohort, the TT-genotype has been associated with reduced circulating HDL-cholesterol levels. This observation has been also confirmed in several RA cohorts. No differences among genotypes have been observed for TC, TG, LDL, ApoB, glucose, or von Willebrand Factor. Interestingly, rheumatoid factor (RF), ESR, or CRP concentrations were also not different but RA patients bearing the TT-genotype were more prone to be anti-CCP positive. <h3>Conclusions</h3> The IL-32 promoter SNP rs4786370 is clearly associated with enhanced IL-32 expression and lower HDL concentrations. In RA patients, the TT-genotype is also associated with anti-CCP positivity. Because both low HDL as well as anti-CCP positivity are linked with higher CVD risk in RA, future studies should reveal whether this IL-32 promoter SNP might be used as a novel CV risk marker. <h3>References</h3> Gabriel SE, et al. Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years. Arthritis Rheum 2003;48:54–8. Joosten LAB, et al. IL-32, a proinflammatory cytokine in rheumatoid arthritis. Proc Natl Acad Sci U S A 2006;103:3298–303. Heinhuis B, et al. Towards a role of interleukin-32 in atherosclerosis. Cytokine 2013;64:433–40. <h3>Disclosure of Interest</h3> None declared
International Commission for Protection against Environmental Mutagens and Carcinogens
Authors: P H Lohman
Journal: Environmental Health Perspectives (1980)

International Commission for Protection Against Environmental Mutagens and Carcinogens Get access JNCI: Journal of the National Cancer Institute, Volume 58, Issue 6, June 1977, Page 1877, https://doi.org/10.1093/jnci/58.6.1877-a Published: 01 June 1977
SAT0144 A Phase I Pharmacokinetic Study Comparing SB2, An Infliximab Biosimilar, And Infliximab Reference Product (Remicade®) in Healthy Subjects: Table 1.
Authors: D. Shin, Y. Kim, Y.S. Kim, R. Fuhr, T. Körnicke
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Objective:</h3> This study was designed to analyze sex-dependent differences in manifest HD patients from the Enroll HD database. <h3>Background:</h3> Neurodegenerative diseases are influenced by a multitude of factors from genetics to the geographic environment. While much is known about the genetics of Huntington’s disease (HD), sex-dependent differences in outcomes for this particular disease have not been fully uncovered. Other neurodegenerative diseases such as Parkinson’s disease have been shown to have clear sex-dependent differences in disease prevalence and onset. Interpretation of these differences has an important role in optimizing treatment and better understanding disease mechanism in HD. <h3>Design/Methods:</h3> Longitudinal study data from baseline and follow-up visits of manifest HD patients (N=8,043) from the Enroll-HD database were analyzed. Linear mixed models were used to assess differences between males and females regarding the motor, behavioral, and cognitive functioning over a series of four annual visits. <h3>Results:</h3> Manifest HD patients showed significant sex-dependent differences in motor and depressive symptoms. While both sexes showed worsening motor and depressive symptoms over the course of 4 annual visits, female patients with HD consistently presented with more severe motor and depressive symptoms than males (p&lt;0.0001). We did not find any difference between male and female patients with HD regarding age at clinical HD diagnosis or the number of CAG repeats. Also, there were no differences between males and females when we evaluated cognitive performance and severity of apathy, irritability/aggressive, psychosis and executive function scores as measured by the Problem Behaviors Assessment – Short (PBA-s) over the four visits. <h3>Conclusions:</h3> Our analyses suggest that females overall have worse motor and depressive symptoms than males in the course of HD progression. The importance of continuing to identify sex differences in disease phenotype, progression, and neuropathology is critical for further advancing our understanding of and treatment for individuals with HD. <b>Disclosure:</b> Dr. Furr-Stimming has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Amneal, Medscape. Dr. Furr-Stimming has received research support from Roche/Genetech Pharmaceuticals, Vaccinex, Uniqure.Dr. Hentosh has nothing to disclose. Dr. Zhu has nothing to disclose. Dr. Furr has nothing to disclose. Dr. Pessoa Rocha has nothing to disclose.
The use of near patient tests in influenza surveillance: Swiss experience and EISS recommendations
Authors: Y Thomas, L Kaiser, W Wunderli
Journal: Eurosurveillance (2003)

Surveillance requires time for analysis and for the communication to physicians. In order to reduce this delay, a new surveillance system based on the use of a near patient test (NPT) has been evaluated. The high specificity of NPT together with the rapidity in obtaining the results, make these tests attractive for surveillance of influenza epidemic in community practice. Such surveillance has been used in several countries including Switzerland. Four different seasons - between 1999 and 2003 - of this type of surveillance experienced in Switzerland have been analysed. The heterogeneity in terms of intensity and type of strains detected during these four epidemics seasons allowed an efficient evaluation. The average gain of time with NPT compared to cell culture was nine days. Furthermore, training of participants appeared to be essential to assure the quality of the surveillance system. A statement on the use of NPTs for influenza surveillance has finally been endorsed by EISS members. Included are recommendations that the network should use the NPTs data, which provides additional information to the classical surveillance systems, as an "early warning" system of a change in influenza activity.
Adeno-associated Vector Toxicity—To Be or Not to Be?
Authors: Hildegard Büning, Manfred Schmidt
Journal: Molecular Therapy (2015)

Vectors based on adeno-associated virus (AAV) are currently in use in numerous gene therapy clinical trials with reports of benefit for patients, for example in treating hemophilia or inherited blindness. An AAV1 vector (Glybera) has recently been approved as the first gene therapy to achieve marketing authorization in Europe. More than 120 clinical trials using AAV have shown vector safety, with a transient and asymptomatic hepatitis as the most severe side effect. In comparison to the widespread use of AAV vectors in clinical, preclinical, and basic research, there has been limited study of the interaction of the parental virus in humans.